MRK
New pill, new problem for cholesterol
Merck just got the FDA green light for LIPFENDRA (enlicitide), an oral once-daily pill approved to help lower LDL cholesterol in adults with hypercholesterolemia, including people with heterozygous familial hypercholesterolemia. Translation: the company is trying to make cholesterol treatment feel a little less like a science project and a little more like taking your vitamins.
Why Wall Street cares
This matters because LIPFENDRA is the first FDA-approved oral PCSK9 inhibitor, which gives Merck a fresh commercial shot in a big market where convenience can matter almost as much as efficacy. The stock was already smiling about it, rising 3.61% to $128.07 and hanging near its 52-week high of $130.29.
The trial receipts
Merck says the approval was backed by two Phase 3 studies in the CORALreef program:
- In CORALreef Lipids, LIPFENDRA cut LDL-C by 56% versus placebo at 24 weeks, or 60% under revised post-hoc handling.
- In CORALreef HeFH, it reduced LDL-C by 59% versus placebo.
- The trials also showed meaningful drops in non-HDL cholesterol and apolipoprotein B, which is the kind of nerdy-but-important data doctors and investors both pretend not to love too much.
The big picture
Merck still has to prove this turns into real-world cardiovascular benefit, and the company says an ongoing study is looking at morbidity and mortality. But for now, this is a clean regulatory win and another reminder that even giant pharma names need fresh products to keep the revenue machine humming. Big picture: one more approved pill won’t replace Keytruda, but it can help diversify the portfolio before the blockbuster gets any older.